参考文献/References:
[1]Liu Y ,Niu XH,Yin XM,et al. Elevated circulating fibrocytes is a marker of left atrial fibrosis and recurrence of persistent atrial fibrillation[J]. J Am Heart Assoc,2018,7(6):e008083
[2] 黄从新,张澍,黄德嘉,等. 心房颤动:目前的认识和治疗的建议-2018[J]. 中国心脏起搏与心电生理杂志,2018,32(4):315-368.
[3] Dzeshka MS,Lip GY,Snezhitskiy V,et al. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications[J]. J Am Coll Cardiol,2015,66(8):943-959.
[4] Tzeis S,Asvestas D,Vardas P,et al. Atrial fibrosis:translational considerations for the management of AF patients[J]. Arrhythm Electrophysiol Rev,2019,8(1):37-41.
[5]King JB ,Azadani PN,Suksaranjit P,et al. Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation[J]. J Am Coll Cardiol,2017,70(11):1311-1321.
[6]Galenko O ,Jacobs V,Knight S,et al. The role of microRNAs in the development,regulation,and treatment of atrial fibrillation[J].J Interv Card Electrophysiol,2019,55(3):297-305.
[7] Moteleb AMAE,Zarif JK,Ali AN,et al. Incidence of atrial fibrosis in non-valvular atrial fibrillation patients and its impact on recurrence after pulmonary vein antral isolation[J]. J Atr Fibrillation,2018,11(1):1773.
[8]Nair GM ,Nery PB,Redpath CJ,et al. The role of renin angiotensin system in atrial fibrillation[J]. J Atr Fibrillation,2014,6(6):972.
[9]Thanigaimani S,Lau DH, Agbaedeng T,et al. Molecular mechanisms of atrial fibrosis:implications for the clinic[J]. Expert Rev Cardiovasc Ther,2017,15(4):247-256.
[10]Groves D,Mihos CG,Larrauri-Reyes M,et al. The use of statins in the treatment and prevention of atrial fibrillation[J]. Cardiol Rev,2016,24(5):224-229.
[11]Kawamura M,Ito H,Onuki T,et al. Candesartan decreases typeⅢprocollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation[J]. J Cardiovasc Pharm acol,2010,55(5):511-517.
[12]Yang D,Yuan J,Liu G,et al. Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1/nuclear factor-kappa B axis[J]. Int J Med Sci,2013,10(7):812-824.
[13]Mayyas F,Alzoubi KH,van Wagoner DR,et al. Impact of aldosterone antagonists on the substrate for atrial fibrillation:aldosterone promotes oxidative stress and atrial structural/electrical remodeling[J]. Int J Cardiol,2013,168(6):5135-5142.
[14]刘刚,张恒. 他汀类药物对于心房颤动防治的研究进展[J].心血管病学进展, 2018,36(6):1068-1071.
[15]Francesco D,Monica G,Alessandro S,et al. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion[J]. Thromb Haemost,2011,106(2):363-370.
[16]Kirchhof P ,Benussi S ,Kotecha D ,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J]. Eur J Cardiothorac Surg,2016,50(5):1-88.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(1):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(1):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(1):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]罗亮 汤宝鹏 周贤惠.三尖瓣反流与心房颤动的研究进展[J].心血管病学进展,2024,(8):681.[doi:10.16806/j.cnki.issn.1004-3934.202.08.003]
LUO Liang,TANG Baopeng,ZHOU Xianhui.Tricuspid Regurgitation and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(1):681.[doi:10.16806/j.cnki.issn.1004-3934.202.08.003]